CEO of AIM, Thomas K. Equels, highlights their robust cash p...

Moomoo AI Nov 15, 2023 20:39

CEO of AIM, Thomas K. Equels, highlights their robust cash position enabling strong clinical and operational performance. He also brings attention to the company's ovarian and pancreatic cancer programs, forecasting value-boosting milestones ahead from them.

Press Release: AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update

Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more

Translate

Report

4865 Views

Comment

Moomoo AI

Moomoo AI Official Account

Your AI assistant for discovering investment opportunities.

4709Followers

0Following

10KVisitors